Recent Highlights
On track to commence Phase II clinical study in the fourth quarter of 2023 for Ropidoxuridine, Shuttle Pharma's lead clinical sensitizer drug candidate.
Successfully completed the
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today